Braveheart Bio Inc., a clinical-stage biopharmaceutical company backed by a16z, is seeking to raise as much as $318.8 million in an initial public offering, adding to a growing pipeline of listings in the sector.
Braveheart Bio Inc., a clinical-stage biopharmaceutical company backed by a16z, is seeking to raise as much as $318.8 million in an initial public offering, adding to a growing pipeline of listings in the sector.
<iframe src="https://statesidedaily.com/embed/cluster/fcd9df8da28497ab797931d2a103592d673bad6a" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="A16z-Backed Biotech Braveheart Seeks $318.8 Million in US IPO"></iframe>
